Review examines how biology may refine pancreatic cancer surgery decisions
The authors describe established and emerging markers of tumor behavior, while emphasizing that many still need prospective validation before routine clinical use.
Moderate evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Pancreatic ductal adenocarcinoma is often classified as operable or inoperable based on how the tumor appears to contact nearby blood vessels on scans. This review argues that anatomy alone may not fully show how aggressive the disease is or whether cancer has already spread in ways that scans cannot detect.
The authors examined research on “biological resectability,” which adds markers of tumor behavior to imaging-based assessment. They describe carbohydrate antigen 19-9 as the most established marker, while circulating tumor DNA and other approaches remain promising but not ready for routine use based on the evidence summarized.
The question reviewed
The researchers conducted a structured narrative review of contemporary evidence on biological resectability in pancreatic ductal adenocarcinoma. They prioritized consensus statements, clinical practice guidelines, meta-analyses, randomized trials, prospective cohorts, and large multicentre studies, then qualitatively classified biomarkers according to their clinical maturity. The abstract does not state the total number of included studies or patients.
What the evidence shows
The review reports that imaging-based anatomical classifications may not identify hidden systemic disease, early recurrence, or which patients are likely to receive meaningful cancer-related benefit from surgery. It identifies carbohydrate antigen 19-9 as the most clinically established biomarker, with interpretation affected by biliary conditions, response to treatment, and multidisciplinary assessment. Circulating tumor DNA may help with molecular staging and recurrence-risk assessment, but prospective interventional validation remains limited. Transcriptomic subtypes, PET-derived measures, radiomics, and combined biomarker models are described as providing additional biological information but as largely investigational.
Who this may apply to
This review is relevant to people with pancreatic ductal adenocarcinoma because it discusses how imaging findings and biological markers may be considered in treatment planning. However, it does not establish that any particular biomarker improves outcomes, and the findings should not be treated as applying uniformly to every patient.
Why it matters
The review highlights why the appearance of a pancreatic tumor on scans may not provide a complete picture of disease behavior. In principle, combining anatomical information with biological markers could help researchers and clinicians study treatment sequencing and patient selection more precisely. However, this review does not show that biomarker-guided decisions improve survival or other patient outcomes, and it does not establish a routine test strategy. The findings concern human cancer research; no animal or laboratory findings are presented as evidence here, although the review may include studies using different research methods in its cited literature that are not detailed in the abstract.
Limitations & evidence assessment
The review is narrative and qualitatively synthesizes selected studies rather than providing a pooled estimate of effects. The abstract does not report the number or detailed characteristics of included studies, and it does not describe a formal risk-of-bias assessment. The review notes that prospective validation, standardized testing, and biomarker-guided clinical trials are still limited, especially for circulating tumor DNA, molecular subtypes, PET measures, radiomics, and combined models. These limitations mean the findings describe an evolving research area rather than establishing a proven decision rule.
Why this evidence level: This is a structured narrative review that considers guidelines, consensus statements, trials, observational studies, and other research. Because the evidence was synthesized qualitatively rather than through a formal systematic review or meta-analysis, and several biomarkers remain investigational, the overall level is rated moderate rather than high.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Annali Italiani di Chirurgia · 2026 · DOI: 10.62713/aic.4732
This systematic review examined human studies of long-term quality of life and depressive symptoms after fracture-related infection, a serious infection involving a broken bone. Across 15 studies, physical quality-of-life scores appeared lower than United States population norms, while evidence about mental quality of life and depressive symptoms was less consistent. The researchers said differences among studies and generally limited study quality prevent definitive conclusions.
Researchers reviewed 18 randomized trials involving 16,573 adults undergoing noncardiac surgery. Compared with standard blood pressure management, higher or individualized blood pressure targets were associated with lower risks of postoperative delirium and surgical-site infection, but showed no clear differences in several other outcomes.
This systematic review and meta-analysis examined standalone physical activity programs in pregnant or postpartum women. Across 17 randomized trials, physical activity was associated with lower depressive symptom scores in several analyses, while evidence about anxiety symptoms during pregnancy was inconclusive.
